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Pretreatment serum FGF-23 levels predict the efficacy of cal-
citriol therapy in dialysis patients.
Background. The predictor for the result of calcitriol ther-
apy would be useful in the clinical practice of secondary hy-
perparathyroidism. Fibroblast growth factor-23 (FGF-23) is a
newly found circulating phosphaturic factor. Its circulating level
is elevated in uremia.
Methods. Dialysis patients with plasma intact parathyroid
hormone (iPTH) levels greater than 300 pg/mL were included
in the study. Calcitriol was intravenously injected three times a
week. The patients whose plasma iPTH levels dropped below
300 pg/mL within 24 weeks were defined as those who had been
successfully treated. A sandwich enzyme-linked immunosor-
bent assay (ELISA) system that detects human FGF-23 was
applied.
Results. Sixty-two patients were analyzed. The pretreatment
FGF-23 levels were related to the iPTH levels, calcium × phos-
phate product levels, and history of active vitamin D therapy.
The pretreatment FGF-23, iPTH, and calcium levels were lower
in the patients who would be successfully treated with calcitriol.
A logistic regression study revealed that the pretreatment iPTH
and FGF-23 levels significantly affected the therapy results.
Analyses using a receiver-operated curve revealed that FGF-23
was the best screening test for identifying patients with future
refractory response to calcitriol therapy. The treatment would
be successful in 88.2% of those with FGF-23 ≤9860 ng/L and
iPTH ≤591 pg/mL, while it would be successful in only 4.2% of
those with FGF-23 >9860 ng/L and iPTH >591 pg/mL.
Conclusion. Pretreatment serum FGF-23 levels were a good
indicator in predicting the response to calcitriol therapy. The
measurement of serum FGF-23 levels, especially in combination
with iPTH levels, is a promising laboratory examination for the
clinical practice of secondary hyperparathyroidism.
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Secondary hyperparathyroidism is a common compli-
cation among long-term dialysis patients, and in many
cases, intermittent intravenous calcitriol administration is
an effective therapy [1]. However, refractoriness to medi-
cal therapy occurs in cases with developed hyperparathy-
roidism, presumably due to changes in the biological
properties of the parathyroid cells [2–4]. Continuing med-
ication with active vitamin D metabolites in patients with
refractory secondary hyperparathyroidism is not only in-
effective, but is also likely to worsen their prognosis be-
cause of the medication’s unfavorable effects on calcium
and phosphate metabolism [5, 6].
It would therefore be useful to predict this refractori-
ness before initiation of the calcitriol therapy. In this re-
gard, pretreament plasma intact parathyroid hormone
(iPTH) levels and serum calcium (Ca) levels have been
found to influence the effectiveness of active vitamin D
therapy, and ultrasonographic parathyroid morphometry
may help to predict this effectiveness [7, 8]. Serum inor-
ganic phosphate (Pi) may also be implicated in the re-
fractoriness of secondary hyperparathyroidism [9]. The
above factors are currently used as predicting factors in
clinical practice; their reliability, however, remains unsat-
isfactory. As such, the identification of other indicators
that can predict the effectiveness of calcitriol therapy
would certainly improve the quality of therapy of sec-
ondary hyperparathyroidism.
Fibroblast growth factor-23 (FGF-23) [10] is a natu-
ral circulating phosphaturic factor that was discovered
in samples obtained from patients with autosomal-
dominant hereditary rickets [11] and tumor-related os-
teomalacia [12]. Circulating FGF-23 seems to play a role
in the regulations of phosphaturisis and vitamin D 1-a
hydroxylase activity [13–17].
Circulating FGF-23 levels are elevated in patients
with chronic renal failure [18–20], and these levels may
play an important role in the development of secondary
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hyperparathyroidism in predialysis patients [21]. Circu-
lating FGF-23 levels affect the future development of sec-
ondary hyperparathyroidism in dialysis patients with mild
secondary hyperparathyroidism. As such, it is possible
that pretreatment circulating FGF-23 levels may allow
us to predict the refractoriness to calcitriol therapy.
We have therefore carried out a prospective clinical
study. The aim of this study was to verify the impact of
pretreatment serum FGF-23 levels in predicting the re-
fractoriness to calcitriol therapy in dialysis patients with
moderate to severe secondary hyperparathyroidism.
METHODS
Patients
Chronic hemodialysis patients whose plasma iPTH lev-
els were greater than 300 pg/mL were included in the
study. Patients with malignancy or chronic inflammatory
diseases were excluded. The study was designed accord-
ing to the Helsinki Declaration, and was approved by the
ethics committees of the medical facilities involved. The
patients were duly informed about the study, and written
consent was obtained before enrollment.
Methods
The washout period consisted of ceasing the use of ac-
tive vitamin D agents four weeks prior to initiation of the
study. After completion of the washout period, 1 lg of
calcitriol was intravenously injected three times per week
at the end of every dialysis session as an initial dosage.
Thereafter, the amount of calcitriol per injection varied
between 0.5 and 1.5 lg so that the serum Ca concen-
trations would not exceed 11.0 mg/dL, or so the Ca ×
inorganic phosphate (Pi) product would not exceed 75
(mg/dL)2 on the third day after the last dialysis session.
Hemodialysis conditions, including dialyzers, dialysate
compositions, and anticoagulants, remained unchanged
throughout the study period. The Ca concentration of the
dialysate was 3.0 mEq/L. The goal of the treatment was
to reduce the iPTH levels to less than 300 pg/mL. The
treatment was continued for the 24 weeks of the study
period unless the goal of the treatment was achieved, or
unless one of the following events occurred: (1) the use
of other active vitamin D analogs, glucocorticoid agents,
bisphosphonates, or any other antiosteoporotic agents;
(2) hypercalcemia with the serum Ca levels exceeding
11.5 mg/dL; and (3) hyperphosphatemia with the serum
Pi levels exceeding 10.0 mg/dL on the third day after the
last dialysis session, despite the increased dose of oral
phosphate binders. Those patients with hypercalcemia,
hyperphosphatemia, or any other harmful events associ-
ated with the calcitriol therapy were subjected for surgical
parathyroidectomy after withdrawing from the study. The
measured serum Ca levels were adjusted with the albu-
min levels as follows when they were lower than 4.0 g/dL:
Ca = measured Ca levels + [4.0− albumin levels (g/dL)
× 0.8] mg/dL. The corrected serum Ca is given through-
out the paper. The treatment was also discontinued if any
other intolerable events occurred.
The serum Ca, Pi, albumin, and plasma iPTH levels
were monitored at least once every four weeks in each
dialysis unit. The plasma iPTH levels were measured
with a two-site immunoradiometric method (Nichols In-
stitute, San Juan Capistrano, CA, USA). Serum FGF-23
levels were determined with a sandwich enzyme-linked
immunosorbent assay (ELISA) system using two kinds of
monoclonal antibodies requiring the simultaneous pres-
ence of both the N-terminal and C-terminal portions of
FGF-23 (Kainos Laboratories, Inc., Tokyo, Japan) [22].
The interassay variation in the normal and elevated con-
centration range was found to be <6%. All of the blood
samples mentioned above were collected at 9:00 a.m. on
the third day after the last dialysis session.
The effect of treatment was judged 24 weeks after
initiation of the calcitriol therapy. The patients whose
plasma iPTH levels dropped below 300 pg/mL within the
24 weeks without harmful events were defined as those
for whom treatment had been successful.
Statistical analysis
All values are expressed as mean ± SD, and P < 0.05
was considered statistically significant. Paired and un-
paired t tests were applied to compare the results between
groups. A logistic regression method was applied to sort
out the factors that significantly affected the results of
calcitriol therapy. For the logistic analysis, the measured
values were divided into five levels according to the ranks
in order to compare the obtained odds ratios impartially.
An analysis using a receiver-operated curve (ROC) [23,
24] was performed to verify the screening abilities of each
factor to discriminate patients who would be successfully
treated with calcitriol. Statistical computations were per-
formed using an Apple Macintosh G4 computer with the
Stat View 5.0 software (SAS Institute, Inc., Cary, NC,
USA).
RESULTS
The clinical courses
Sixty-two patients were included in the study. Their
general clinical features are listed in Table 1.
None of the patients began to use glucocorticoid
agents, bisphosphonates, or antiosteoporotic agents dur-
ing the study. Calcium bicarbonate was the only oral phos-
phate binder used during the observation period, and the
daily dosage was changed in none of the patients. The
treatment was discontinued in two patients because of
hypercalcemia that exceeded 11.5 mg/dL. The treatment
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Table 1. Summary of the clinical features of all 62 patients included
in the study
Age years Gender Duration of hemodialysis Primary disease
58.9 ± 12.8 M40:F22 120.8 ± 98.5 (M) CGN 44
DMGS 8
NSc 3
Others 4
Unknown 3
Abbreviations are: CGN, Chronic glomerulonephritis; DMGS, diabetic
glomerulosclerosis; Nsc, hypertensive nephrosclerosis.
Table 2. The changes in biochemical data throughout the study
0W 8W 24W
(N = 62) (N = 48) (N = 45)
A
iPTH pg/mL 702 ± 294 614 ± 321 564 ± 329a
Ca mg/dL 9.1 ± 1.0 9.7 ± 9b 9.7 ± 9c
Pi mg/dL 6.0 ± 1.3 6.3 ± 1.1 6.8 ± 1.7b
FGF-23 pg/mL 19771 ± 20780 25354 ± 24063 28823 ± 23128a
0W 8W 24W
B (N = 45) (N = 45) (N = 45)
iPTH pg/mL 758 ± 306 613 ± 310c 564 ± 329c
Ca mg/dL 9.2 ± 1.0 9.6 ± 9c 9.7 ± 9c
Pi mg/dL 6.0 ± 1.3 6.3 ± 1.2a 6.8 ± 1.7c
FGF-23 pg/mL 23192 ± 22171 26640 ± 24583 28823 ± 23128a
Calcitriol therapy reduced the plasma iPTH levels and increased the serum Ca,
Pi, and FGF-23 levels. Samples were obtained three days after the last dialysis
session. All the patients in group A participated (unpaired ± test). Group B
comparised 45 patients who received the calcitriol therapy throughout the 24
weeks (paired ± test). The normal FGF-23 range among healthy volunteers is
26.3 ± 8.4 pg/mL.
aP < 0.05 vs. 0W.
bP < 0.01 vs. 0W.
cP < 0.001 vs. 0W.
goal was achieved in 15 patients before the 24th week. The
remaining 45 patients received calcitriol therapy three
times per week for 24 weeks. Of those 45 patients, the
plasma iPTH levels were below 300 pg/mL in 11 patients,
and above 300 pg/mL in 34 patients at the 24th week.
Table 2 shows the changes in biochemical data through-
out the study. Calcitriol therapy reduced the plasma iPTH
levels, and increased the serum Ca, Pi, and FGF-23 levels.
The pretreatment serum levels of serum FGF-23
The pretreatment Ca × Pi product levels, months after
initiation of the chronic hemodialysis therapy, as well as
previous active vitamin D therapy within one-year period
before the washout period were found to be significantly
related to the pretreatment serum FGF-23 levels (Figs. 1
and 2). The pretreatment iPTH levels also showed a weak
correlation with FGF-23.
Clinical profiles of the successfully treated patients
The pretreatment plasma iPTH, serum Ca, and serum
FGF-23 levels were significantly lower in patients who
would be successfully treated (Fig. 3).
Prediction of successful treatment
The overall successful treatment rate was 26/62
(41.9%). A logistic regression study revealed that the pre-
treatment serum FGF-23 and plasma iPTH levels signifi-
cantly affected the results of calcitriol therapy (Table 3).
An analysis using an ROC was performed to verify the
screening abilities of iPTH, Ca, FGF-23, and Pi levels.
The area under the curve (AUC) obtained by FGF-23
(8429.5) was more than those of iPTH (7970.1, P < 0.05),
Ca (7959.4, P < 0.05), and Pi (5170.9, P < 0.0001). The
maximum value of sensitivity (%) × specificity (%) prod-
uct was 76.9 × 83.3 = 6410.3 by FGF-23, 76.9 × 75.0 =
5769.2 by iPTH, 84.6 × 63.9 = 5406.0 by Ca, and 65.4 ×
44.4 = 2906.0 by Pi, respectively. When 84.6% of sensitiv-
ity was obtained by FGF-23, the corresponding specificity
was 75.0% (Fig. 4, Table 4).
The treatment would be successful in 88.2% of those
with FGF-23 ≤9860 ng/L and iPTH ≤591 pg/mL, while
it would be successful in only 4.2% of those who with
FGF-23 >9860 ng/L and iPTH >591 pg/mL (Table 4).
DISCUSSION
Recent findings demonstrated that FGF-23 plays an
important role in the regulation of phosphate and vita-
min D metabolism [25, 26]. Several lines of evidence indi-
cating that chronic renal failure accompanies significant
increase in serum FGF-23 levels; however, the measure-
ment of serum FGF-23 levels has not been applied as a
clinical laboratory examination. In this study, serum FGF-
23 levels were found to be a good indicator for predict-
ing the refractoriness to calcitriol therapy. It is naturally
understandable that pretreatment iPTH levels affect the
result of calcitriol therapy. To our astonishment, the pre-
dictability of FGF-23 was at least comparable to that of
iPTH itself. Today, the reliability of iPTH and Ca levels
remains unsatisfactory in estimating the refractoriness to
calcitriol therapy, and therefore, the aimless continuation
of the therapy is often performed. Although Pi is recog-
nized as an activating factor for parathyroid function, this
study revealed that pretreatment serum Pi levels could
not predict the result of calcitriol therapy [27]. Neverthe-
less, we do not intend to neglect the need for Pi control
in uremic patients.
Recently, vascular calcification associated with ure-
mia has drawn attention of many researchers [28, 29].
The vascular calcification is caused at least in part by
the overtreatment with active vitamin D therapy [30].
The estimation of the refractoriness to medical therapy
would help avoiding the overtreatment with calcitriol and
reduce the risk of vascular calcification. Thus, the mea-
surement of circulating FGF-23 levels is a promising lab-
oratory examination that may bring an improvement in
the clinical treatment of secondary hyperparathyroidism.
The usefulness was even emphasized when it was applied
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Fig. 1. The pretreatment iPTH levels (A), Ca
× Pi product levels (B), and months after the
initiation of chronic hemodialysis therapy (C)
showed weak correlations with the pretreat-
ment serum FGF-23 levels.
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Fig. 2. The previous active vitamin D ther-
apy within the one-year before the washout
period independently related to the pretreat-
ment serum FGF-23 levels from iPTH levels
or Ca × Pi product levels. Open bars signify
patients who had not been treated with cal-
citriol for at least one year before the washout
period. Closed bars signify patients who had
been treated with calcitriol within one year
before the washout period.
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Fig. 3. The pretreatment plasma iPTH lev-
els, serum FGF-23, and Ca levels were signifi-
cantly lower in the patients for whom treat-
ment had been effective. Open bars signify
patients who could be successfully treated
with calcitriol. Closed bars signify patients for
whom the calcitriol treatment failed.
in combination with iPTH (Table 4). Further prospective
clinical studies are necessary to confirm whether the mea-
surement of circulating FGF-23 levels contributes to the
improved prognosis of uremic patients with secondary
hyperparathyroidism. Moreover, it is of interest whether
the pretreatment serum FGF-23 levels predict the re-
sult of therapy with not only calcitriol, but also calcitriol
analogs such as paricalcitol [31] or maxacalcitol [32].
The mechanisms by which FGF-23 levels are elevated
in dialysis patients remain unknown. The levels in dialysis
patients are not only generally high, but are distributed
across quite a wide range [18–20]. Moreover, the assay
system we applied in this study did not detect an inac-
tive metabolite of FGF-23 [22] that would be cleared
through urinary excretion. Therefore, the elevated lev-
els of serum FGF-23 in dialysis patients cannot simply
be explained by the impairment of glomerular filtration,
and suggest that the accelerated production of FGF-23
may coincidently occur. Parathyroid function showed a
weak but significant correlation with the serum FGF-23
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Table 3. A logistic regression analysis to detect the factors affecting
the results of the calcitriol therapy applying five classified levels
according to the rank of measured values in FGF-23, iPTH, Ca, and Pi
P k2 Odds ratio (95% range)
FGF-23 .0055 7.695 3.075 (1.390–6.800)
iPTH .0066 7.366 2.346 (1.267–4.343)
Ca .5758 .313 1.234 (.591–2.576)
Pi .1112 2.537 .578 (.294–1.135)
The study revealed that higher pretreatment circulating FGF-23 and iPTH
levels are significantly related to the refractoriness of the calcitriol therapy.
FGF-23, −990, 1070–7030, 9860–20500, 20600–29300, 30700− (ng/L); iPTH,
−470, 472–559, 560–675, 690–890, 900− (pg/mL); Ca, −8.0, 8.1–8.8, 8.9–9.3,
9.4–9.9, 10.0− (mg/dL) Pi, −4.6, 4.7–5.4, 5.5-6.2, 6.3–7.1, 7.2− (mg/dL)
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Fig. 4. An analysis using a receiver-operated curve (ROC) to detect the
usefulness of screening tests that discriminate patients with secondary
hyperparathyroidism who would be refractory to the calcitriol ther-
apy. The ROC analysis revealed that the area under the curve (AUC)
obtained by FGF-23 (8429.5) was more than those of iPTH (7970.1,
P <.05), Ca (7959.4, P <.05), and Pi (5170.9, P <.0001).
levels. However, the parathyroid glands themselves were
unlikely to produce FGF-23 since fgf-23 mRNA was not
detectable in parathyroid glands removed from dialy-
sis patients with severe secondary hyperparathyroidism
(data not shown). On the other hand, a recent study
suggested that osteoblasts are one of likely candidates
that produce circulating FGF-23 [33]. Given the fact that
hyperparathyroidism generally accompanies increased
activity of bone metabolism, the positive correlation be-
tween iPTH and FGF-23 levels may reflect the indirect
stimulation of FGF-23 production by PTH via bone cells.
Interestingly, serum FGF-23 levels were rather ele-
vated, while iPTH levels were decreased, in response to
the calcitriol therapy in this study. This finding could rea-
sonably explain why previous active vitamin D therapy
affected the pretreatment serum FGF-23 levels. The num-
ber of months since the initiation of chronic hemodialysis
therapy may reflect the total amount of active vitamin D
agents used, as these agents had not been used before the
initiation of hemodialysis therapy in any of these patients.
Table 4. The discrimination of patients who would be successfully
treated with calcitriol by the combination of FGF-23 and iPTH
FGF-23 ≤ 9860 ng/L FGF-23 >9860 ng/L
iPTH ≤ 591 pg/mL 15/17 5/12
iPTH >591 pg/mL 5/9 1/24
FGF-23 discriminated those patients with sensitivity = (15 + 5)/26 = 76.9%
and specificity = (7 + 23)/36 = 83.3%, and so did iPTH with sensitivity = (15 +
5)/26 = 76.9% and specificity = (4 + 23)/36 = 75.0%, respectively. On the other
hand, 15/17 = 88.2% of those patients with FGF-23 ≤9860 ng/L and iPTH ≤591
pg/L would be successfully treated with calcitriol, while the treatment would be
failed in 23/24 = 95.8% of those who were treated with FGF-23 >9860 ng/L and
iPTH >591 pg/L.
The longer history of active vitamin D therapy may also
be related to the refractoriness to the treatment.
Circulating FGF-23 levels decrease after surgical
parathyroidectomy [34]. Therefore, it must not be the
decreased action of PTH, but the increased action of
1,25(OH)2 vitamin D3 (1,25D) that caused the elevation
of circulating FGF-23 levels in these patients. FGF-23 has
a strong suppressive effect on vitamin D-1 a hydroxylase
activity in the kidney [25, 35, 36]. On the other hand, ad-
ministration of 1,25D induced FGF-23 production in mice
[25]. FGF-23 production may be promoted by 1,25D ad-
ministration through decreasing PHEX expression [37],
which is a possible regulator of fgf-23 mRNA expression
[33]. The cross-talk regulation between FGF-23 and cal-
ciotropic hormones in mineral metabolism is suggested,
and further studies are needed to elucidate the precise
mechanism.
The fact that calcitriol therapy increases FGF-23 lev-
els seems rather convenient from the perspective of pre-
dicting the refractoriness of calcitriol therapy based on
FGF-23 levels. Although a four-week active drug washout
period was set in this study, it would be difficult to have
such a period when the measurement of circulating FGF-
23 levels is carried out in clinical practice. However,
because calcitriol therapy did not decrease the FGF-23
levels, the levels after calcitriol therapy would not un-
derestimate the refractoriness of the parathyroid gland
against calcitriol therapy, especially when it is applied in
combination with iPTH measurement.
CONCLUSION
Pretreatment serum FGF-23 levels were a good indi-
cator in predicting the efficacy of the calcitriol therapy in
dialysis patients with moderate to severe secondary hy-
perparathyroidism. As such, the measurement of serum
FGF-23 levels is a promising laboratory examination in
the clinical treatment of secondary hyperparathyroidism,
especially when applied in combination with iPTH mea-
surement. Further prospective clinical studies are neces-
sary to confirm whether the measurement of circulating
FGF-23 levels contributes to the improved prognosis of
the patients.
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